- Trials with a EudraCT protocol (108)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
108 result(s) found for: Protein Sequencing.
Displaying page 1 of 6.
EudraCT Number: 2019-002225-30 | Sponsor Protocol Number: 69HCL18_0957 | Start Date*: 2019-07-18 | ||||||||||||||||
Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
Full Title: Impact of low protein diet supplemented with ketoanalogues on uremic toxins production and glucose metabolism in chronic kidney disease_KETO GUT study | ||||||||||||||||||
Medical condition: chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001767-67 | Sponsor Protocol Number: PTC124-GD-045-DMD | Start Date*: 2020-01-30 |
Sponsor Name:PTC Therapeutics, Inc. | ||
Full Title: Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment with Ataluren | ||
Medical condition: Non-Sense Mutation Duchenne Muscular Dystrophy (nmDMD) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-004355-33 | Sponsor Protocol Number: MH002-UC-201 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:MRM Health NV | |||||||||||||
Full Title: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Mechanistic Effects, and Effects on Disease Activity of MH002 in Subjects with Mild to Moderate Ulcerative Colitis: A First-in... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004370-96 | Sponsor Protocol Number: LG-TCS-AD | Start Date*: 2019-02-15 | |||||||||||
Sponsor Name:Jacob Pontoppidan Thyssen | |||||||||||||
Full Title: The effects of topical corticosteroid use on insulin sensitivity and bone turnover | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003530-13 | Sponsor Protocol Number: 18072011 | Start Date*: 2011-12-20 | |||||||||||
Sponsor Name:Brighton & Sussex University Hospitals NHS Trust | |||||||||||||
Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer | |||||||||||||
Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003768-31 | Sponsor Protocol Number: NNF18OC0052256 | Start Date*: 2019-12-05 |
Sponsor Name:Lungemedicinsk Forskningsenhed | ||
Full Title: Effects of azithromycin treatment on anti-viral immunity in patients with asthma and COPD. | ||
Medical condition: COPD and asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003335-29 | Sponsor Protocol Number: SIOPEATRT01 | Start Date*: 2021-04-15 |
Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH | ||
Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig... | ||
Medical condition: atypical teratoid/rhabdoid tumours (ATRT) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001120-54 | Sponsor Protocol Number: SQ167015 | Start Date*: 2016-07-25 |
Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust | ||
Full Title: Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage? | ||
Medical condition: Recurrent miscarriage | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001088-58 | Sponsor Protocol Number: SELLY | Start Date*: 2020-03-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | ||||||||||||||||||
Full Title: SEntinel Lymph node in EarLY ovarian cancer: the SELLY protocol | ||||||||||||||||||
Medical condition: ADVANCED OVARIAN CANCER | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004241-32 | Sponsor Protocol Number: EDOLAS | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI | |||||||||||||
Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression | |||||||||||||
Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004467-13 | Sponsor Protocol Number: 012255 | Start Date*: 2018-10-02 | |||||||||||
Sponsor Name:Barts Health NHS Trust | |||||||||||||
Full Title: A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancrea... | |||||||||||||
Medical condition: Stage IV pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004340-30 | Sponsor Protocol Number: M15-538 | Start Date*: 2020-06-08 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003970-41 | Sponsor Protocol Number: CRU3 | Start Date*: 2017-07-06 | |||||||||||
Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA | |||||||||||||
Full Title: A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS | |||||||||||||
Medical condition: Anaplastic Large Cells Lymphoma (ALCL) ALK+ | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002359-39 | Sponsor Protocol Number: 213406 | Start Date*: 2020-09-18 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS | ||||||||||||||||||
Medical condition: Recurrent or refractory solid tumour | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing) HU (Ongoing) CZ (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005157-75 | Sponsor Protocol Number: EMN12/HO129 | Start Date*: 2015-08-06 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients | |||||||||||||
Medical condition: Primary plasma cell leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Ongoing) NO (Completed) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000803-20 | Sponsor Protocol Number: C1071006 | Start Date*: 2022-11-02 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENA... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) ES (Restarted) CZ (Ongoing) BE (Ongoing) DE (Ongoing) FI (Ongoing) HU (Ongoing) FR (Ongoing) GR (Ongoing) DK (Ongoing) AT (Ongoing) IT (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003105-33 | Sponsor Protocol Number: EMN12/HO129 | Start Date*: 2017-08-02 | |||||||||||
Sponsor Name:HOVON | |||||||||||||
Full Title: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients | |||||||||||||
Medical condition: Primary plasma cell leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002428-10 | Sponsor Protocol Number: KTxSGLT2i-22 | Start Date*: 2023-03-06 | |||||||||||
Sponsor Name:Oslo Univeristy Hospital - Rikshospitalet | |||||||||||||
Full Title: CAN DAPAGLIFLOZIN PRESERVE STRUCTURE AND FUNCTION IN TRANSPLANTED KIDNEYS? | |||||||||||||
Medical condition: Kidney transplanted patients. Looking at the effect of SGLT2 inhibitor on graft survival by repeated eGFR measurements, measured GFR, kidney graft biopsies to evaluate inflammation, fibrosis and va... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002163-17 | Sponsor Protocol Number: 15-138 | Start Date*: 2018-10-25 |
Sponsor Name:RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A) | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. | ||
Medical condition: Friedreich Ataxia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2020-004486-40 | Sponsor Protocol Number: R3918-PNH-2021 | Start Date*: 2022-04-04 | |||||||||||
Sponsor Name:REGENERON PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A... | |||||||||||||
Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) GR (Ongoing) HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.